1 Quantum Computing Stock to Buy Hand Over Fist in December

Quantum computing has emerged as a new AI investment theme in 2025, driving speculative rallies in pure-play names (Rigetti up as much as ~1,770% and D‑Wave ~1,500% at peaks) even as these stocks have pulled back sharply and face risks including insider selling and weak fundamentals; IonQ has spent roughly $2.5 billion on acquisitions funded by stock, Rigetti’s CEO sold $11 million of stock in May, and management signals meaningful revenue is years away. Nvidia, meanwhile, has seen shares fall up to ~5% since its Nov. 19 quarter but trades at a forward P/E of ~23.5, cites >$300 billion backlog for Blackwell/Rubin GPUs, and has multibillion-dollar partnerships (Anthropic) plus new quantum roadmap products (NVQLink/CUDA‑Q), leading the author to recommend buying the dip given large data‑center capex forecasts (~$5 trillion through 2030).

Analysis

Market structure: Hyperscalers (AMZN, GOOGL, MSFT) and Nvidia (NVDA) are the primary beneficiaries — NVDA captures GPU, interconnect, and software economics with a reported ~$300bn backlog, translating to multi-year revenue visibility. Pure-play quantum names (IONQ, RGTIW, QBTS) are price-action losers: heavy insider selling, stock-funded M&A, and R&D-stage business models imply dilution and binary commercialization risk that can compress multiples by 50–80% if no revenue inflection occurs within 12–24 months.

Risk assessment: Near-term (days–weeks) downside risk centers on earnings/capex guidance from hyperscalers and additional insider dumps in pure-plays; medium-term (3–12 months) tail risks include a hyperscaler capex pause (a 20–30% cut would materially hit NVDA growth) or export/regulatory actions that limit GPU sales. Hidden dependencies include hyperscaler timing of model training cycles, foundry supply constraints for advanced nodes, and software lock-in (CUDA-Q adoption rates) which drive second-order revenue for NVDA. Key catalysts: Anthropic/Rubin deployments, quarterly capex guidance (next 30–90 days), and any credible commercial quantum proof-point.

Trade implications: Favor a core long in NVDA sized 2–4% of risk capital with layered entry; hedge with 1–2% notional short exposure to IONQ/RGTIW/QBTS or buy puts on those names to protect against further de-risking. Options: buy 12–18 month NVDA LEAP calls (buy Jan 2027 20–30% OTM) sized ~1% notional and sell short-dated (30–60 day) calls to finance; use bear-put spreads on pure-plays (60–120 DTE) to exploit elevated IV and downside skew. Rotate defensive proceeds into data-center suppliers and software exposure (PLTR) if NVDA execution remains intact.

Key Decisions for Investors

• Establish a 2–4% portfolio long in NVDA (scale-in over 2–4 weeks); add 1% notional in Jan-2027 LEAP calls (20–30% OTM) as convex upside—trim to lock gains if NVDA rallies >25% or forward P/E expands above 30.
• Open a net-short tactical position (1–2% portfolio risk) across IONQ, RGTIW, QBTS: either short shares or buy 60–120 DTE put spreads (e.g., 10–25% ITM / 30–50% OTM protection) to exploit likely dilution/insider-selling pressure; reduce if any of these report >50% YoY revenue growth or positive commercial contracts.
• Implement a pair trade: long NVDA vs short IONQ equal-dollar notional (hedge beta) sized 1–2% to capture secular GPU demand vs speculative quantum froth; rebalance if NVDA underperforms hyperscaler capex guidance by >10% in next two quarters.
• Use options flow to monetize near-term volatility: sell 30–60 DTE covered calls on 25–50% of NVDA position to capture premium while maintaining upside; allocate proceeds to buy puts on pure-play quantum names as insurance.
• Monitor three near-term catalysts before increasing size: hyperscaler capex guidance (next 30–60 days), NVDA quarterly revenue/backlog conversion (next report), and any material insider/M&A activity in pure-plays — act within 5 trading days after catalyst confirmation.